
zzso is the first US Food and Drug zzso zzso zzso inhibitor and is indicated for the treatment of zzso zzso zzso zzso We conducted a phase I study to determine the zzso dose and zzso of zzso in patients with zzso zzso 

Patients had solid zzso and acceptable bone zzso and zzso zzso zzso dysfunction was zzso as mild, moderate, or severe by the National Cancer Institute zzso zzso Working Group zzso Fifteen patients with normal liver function were enrolled as zzso All patients received a single zzso dose of zzso for zzso zzso One week later, daily zzso dosing was begun and continued until toxicity or disease progression zzso The daily zzso dose was escalated within each zzso dysfunction zzso zzso plasma zzso were zzso by a validated liquid zzso mass zzso zzso and modeled zzso 

zzso patients were enrolled zzso age, 59 years; zzso zzso zzso zzso 42 patients had zzso dysfunction (16 mild, 15 moderate, and 11 zzso Eight of nine patients with zzso toxicity had grade 4 zzso The recommended zzso doses in mild, moderate, and severe zzso dysfunction were zzso zzso and 100 zzso respectively, on the daily continuous zzso There were no significant differences in zzso zzso parameters among the normal or zzso dysfunction zzso Disease stabilization was noted in 12 zzso Of five patients with zzso zzso zzso one patient had a partial response, and four patients had stable zzso A patient with zzso zzso zzso had stable disease for more than 2 zzso 

Patients with varying degrees of zzso dysfunction require appropriate dose reduction even though zzso zzso are zzso 

